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Abstract Decreased level of high density-lipoprotein
cholesterol (HDL-C) is a rigorous predictor for future
cardiovascular events. Much effort is being made to
develop HDL-C–raising pharmacotherapies in the attempt
to avert the pandemic of atherosclerotic disease. Impor-
tant properties by which HDL-C–raising compounds are
effective involve improvement of cholesterol uptake from
macrophages in plaque for transport back to the liver,
improvement of endothelial function, and anti-inflammatory
effects. Vascular imaging can aid in the determination which
HDL-C–raising compounds are effective. Ultrasound and
MRIhaveprovedsuitableforassessmentofstructuralchanges
of the vessel wall. Ultrasound can also be used or assessment
of endothelial function. 18F-fluordeoxyglucose positron
emission tomography has opened up the possibility to
assess vessel wall inflammation. In this article we
discuss these various imaging techniques and how they
can assess efficacy as well as provide pathophysiologic
information on the mechanism of action of novel HDL-
C–raising drugs.
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Introduction
High-density lipoproteins (HDL) are small vesicles com-
prised of phospholipids and stabilizing proteins, such as
apolipoprotein A-I and A-II (ApoA-I, ApoA-II), that are
produced by the liver to carry cholesterol and triglycerides
in the blood stream. Prospective epidemiologic studies
demonstrated that an increase of 1 mg/dL in HDL-C is
associated with a 2%–3% reduction in the risk of
cardiovascular events, and the predictive value of HDL-C
is complementary to that of low-density lipoprotein
cholesterol (LDL-C) levels [1]. This has led to the wide
acceptance of the hypothesis that HDL has protective
properties against atherosclerosis.
One of the major protective mechanisms of action of
HDL is the uptake of cholesterol from peripheral cells, such
as foam cells in atherosclerotic plaques, after which
cholesterol is either transported directly to the liver for
excretion into the bile, or shuttled to LDL. This process is
also termed “reverse cholesterol transport” (RCT). Other
important properties of HDL include favorable effects on
endothelial function as well as anti-inflammatory effects [2].
As a result of the pivotal role of HDL in protection against
atherosclerosis, HDL has become the most promising target
for pharmacologic intervention. In order to assess the efficacy
of rapidly evolving novel HDL-C–raising compounds, non-
invasive vascular imaging techniques can be utilized. An
appealing facet of vascular imaging is that it can specifically
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DOI 10.1007/s11883-011-0176-1address relevant processes in atherosclerosis, such as changes
in vessel wall thickness, plaque size and composition,
endothelial function, and plaque inflammation, which can
aid the decision making on whether or not to proceed testing
the drug in a large clinical endpoint study. In this review, we
reflect on the various imaging techniques that can be used to
assess the efficacy of HDL-C–raising therapies.
Intima-Media Thickness Measurement
Carotid intima-media thickness (CIMT) can be measured non-
invasively with B-mode ultrasound. The lumen-intima and
media-adventitia interfaces of the carotid artery walls cause
reflectionoftheultrasoundwaves,whichbecomevisibleasthe
typical “double line pattern” on the ultrasound image (Fig. 1).
Intimal thickening is the first manifestation of atherosclerosis
and is caused by the accumulation of lipids in the artery wall
that occurs over the course of decades. Therefore, favorable
effects of HDL-C–raising drugs on CIMT progression may
be related to improvement of the RCT.
Ultrasound CIMT offers good inter-scan and good inter-
and intra-observer reproducibility with intraclass correlation
coefficients above 0.90 in recent trials [3]. Furthermore, the
measurement of CIMT has been validated in various large,
prospective, epidemiologic studies. In fact, a systematic
review and meta-analysis showed that the pooled estimates
of hazard ratios per 0.10-mm difference in CIMT, adjusted
for age and sex, are 1.15 for myocardial infarction (MI) and
1.18 for stroke (Table 1)[ 4]. The fact that no ionizing
radiation is involved, no contrast agent needs to be injected,
and the fact that ultrasound is relatively cheap and widely
Fig. 1 Various imaging modalities that can address different
processes in atherosclerosis. Upper left: brachial artery endothelial
function measurement with ultrasound (courtesy of Eric de Groot).
The brachial artery diameter is measured at baseline and after cuff
release and used to calculate the flow-dependent vasodilatation. Lower
left: carotid vessel wall thickness measurement by ultrasound on the
left (courtesy of Eric de Groot) and MRI on the right (courtesy of Aart
Nederveen). Upper right: MRI of carotid artery plaque composition
(courtesy of Aart Nederveen). Lower right: 18F-fluordeoxyglucose
positron emission tomography (FDG-PET)/CT imaging of carotid
artery plaque. Plaque calcification is visible on the CT scan (courtesy
of Jan Bucerius)
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ment for assessment of cardiovascular drug efficacy.
Various epidemiologic trials have investigated the relation-
ship between HDL-C levels and CIMT and showed that low
levels of HDL-C were associated with thicker CIMT.
Recently, the Multi-Ethnic Study of Atherosclerosis, a cross-
sectional study in 4792 subjects without coronary artery
disease (CAD) or lipid-lowering therapy, showed that men
withHDL-C ≤40 mg/dL and women withHDL-C ≤50mg/dL
with otherwise normal lipid levels had 0.021-mm thicker
CIMT than subjects with normal HDL-C levels [5]. The
Atherosclerosis Risk in Communities (ARIC) study showed
in 15,792 subjects that decreased HDL-C levels were
associated with accelerated progression of CIMT in a
longitudinal follow-up study [6].
Furthermore, studies in families with genetic mutations
in ATP-binding cassette transporter A1 (ABCA1), lecithin:
cholesteryl acyltransferase (LCAT), or ApoA-I, causing
marked decrease in HDL-C levels, showed that carriers had
increased CIMT when compared to unaffected age-matched
controls [7], supporting a causal role for HDL in protection
against atherogenesis.
HDL-C–raising therapies have been investigated in
various CIMT trials (Table 1). The efficacy of niacin on
CIMT progression has been investigated in the Arterial
Biology for the Investigation of the Treatment Effects of
Reducing Cholesterol–HDL and LDL Treatment Strategies
(ARBITER 2, 3 and 6–HALTS) [8, 9, 10￿￿], the Cholesterol
Lowering Atherosclerosis Study CLAS [11], and a study by
Mack et al. [12]. These studies showed that niacin
effectively slows atherosclerosis progression and its efficacy
is already visible after a single year of therapy. A caveat,
however, is that in addition to HDL-C, niacin also affects
LDL-C, triglycerides, remnant particles, lipoprotein (a), and
inflammatory biomarkers, so changes in CIMT cannot solely
be attributed to its HDL-C–raising properties.
Another drug that raises HDL-C by inhibition of choles-
teryl ester transfer protein (CETP) inhibition, torcetrapib, was
investigated in the Rating Atherosclerotic Disease Change by
Imaging with a New CETP Inhibitor (RADIANCE) 1 [3]a n d
2[ 13] trials. The trials did not show any benefit of
torcetrapib on CIMT progression. In fact, in RADIANCE
1, an increase of CIMT was observed. These unexpected
findings were in line with the outcome of the morbidity and
mortality study in 15,067 patients at high CAD risk, in
which a marked increase in all-cause mortality was observed
in the torcetrapib group [14]. Later studies revealed off-target
effects of torcetrapib that may have annihilated the cardio-
vascular benefit of raising HDL. Torcetrapib raised blood
pressure, accompanied by an upregulation of the renin
angiotensin system and the endothelin system in both
adrenals as well as aortic tissue [15].
MRI of Vessel Wall Thickness, Plaque Size,
and Composition
MRI has emerged as one of the leading in vivo imaging
techniques for atherosclerosis because it enables imaging of
all stages of atherosclerosis, from healthy vessels to
advanced disease (Fig. 1)[ 16, 17]. By obtaining multiple
images, each differently weighted for the spin-lattice
relaxation time (T1), the spin-spin relaxation time (T2),
and the proton density (PD), plaque components such as
intra-plaque hemorrhage, lipid-rich necrotic core, and
calcification can be discriminated [16].
Assessment of vessel wall thickening by MRI reflects the
accumulation of lipids in the intima of the vessel wall in the
earlier stages of atherosclerosis, whereas identification of
lipid-rich necrotic core depicts advanced atherosclerosis.
Assessing changes in either vessel wall thickening or lipid-
richnecroticcoresizebytreatmentwithHDL-C–raisingdrugs
Table 1 Various imaging modalities that can be used for assessment of HDL-C–raising drugs
Imaging
modality
Outcome parameter Reproducibility
(ICC)
Predictive value of
future CVD
Correlation with HDL-C HDL-C–raising drugs
investigated
Vessel wall
thickening
US IMT >0.90 [3] HR 1.15 per 0.10 mm
IMT difference [4]
Yes [5–7] Niacin [8, 9, 10￿￿, 11, 12],
torcetrapib [13]
Plaque
vulnerability
MRI MWA or NWI >0.95 [17] Under investigation [23] Yes [24￿] Niacin [27], dalcetrapib
MRI AHA plaque type, LRNC,
IPH, calcification
>0.90 [18]H R 5 –17 for presence of IPH
or plaque rupture [19, 20,
21, 22￿]
No [25, 26] Niacin [28]
Endothelial
function
US FMD (%) >0.85 [29] HR 0.84–0.91 per SD of FMD
[30, 31￿￿]
Yes [30, 32] Niacin [33, 34], rHDL
[35, 36], dalcetrapib [37]
Vessel wall
inflammation
FDG-PET SUV or TBR >0.90 [46] Under investigation [23] Yes [44, 45] Dalcetrapib
AHA—American Heart Association; CVD—cardiovascular disease; FDG-PET—18F-fluordeoxyglucose positron emission tomography; FMD—
flow-mediated vasodilatation; HDL-C—high-density lipoprotein cholesterol; HR—hazard ratio; ICC— intraclass correlation coefficient; IMT—
intima-media thickness; IPH—intraplaque hemorrhage; LRNC—lipid-rich necrotic core; MWA—mean wall area; NWI—normalized wall index;
rHDL—reconstituted high-density lipoprotein; SUV—standard uptake value; TBR—target-to-background ratio; US—ultrasound.
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Imaging of vessel wall thickness has proved to be highly
reproducible, with intraclass correlation coefficients above
0.95 [17]. Imaging of plaque size and composition has also
shown good reproducibility, with intraclass correlation
coefficients above 0.90 (Table 1)[ 18].The predictive value
for future cardiovascular events of imaging vessel wall
thickness by MRI has not yet been investigated. However,
MRI of vessel wall thickness is highly correlated with
ultrasound CIMT [17], so it is to be expected that the
predictive value of both modalities will be in the same
order of magnitude.
The relation between plaque size and composition has
been investigated in various MRI studies. Underhill et al.
[19] showed that compositional changes in MRI-
characterized atherosclerotic plaque were associated with
future risk of plaque surface disruption. In 85 patients with
baseline 50%–79% carotid stenoses, increased plaque
surface disruption at 3 years was predicted by baseline
lipid-rich necrotic core size and intraplaque hemorrhage
[19]. Takaya et al. [20] showed in a longitudinal follow-up
study in 154 patients with asymptomatic 50%–79% carotid
stenosis that presence of thin or ruptured fibrous cap and
intraplaque hemorrhage were strong predictors of future
ipsilateral cerebrovascular events with hazard ratios of 17.0
(P<0.001) and 5.2 (P=0.005), respectively. Similar results
were found in a prospective longitudinal cohort study in 64
symptomatic patients where intraplaque hemorrhage was a
strong predictor for future ipsilateral cerebrovascular events
(hazard ratio 9.8; P=0.03) [21].
Parmar et al. [22￿] investigated 78 patients within 48 h of
onset of transient ischemic attack (TIA) or stroke symp-
toms. Carotid MRI was performed in all participants, and
plaques were classified according to the American Heart
Association classification system. Type VI plaque (cap
rupture, hemorrhage, and/or thrombosis) was the strongest
predictor of a diagnosis of ipsilateral TIA or stroke, with an
odds ratio of 11.7 [22￿]. Larger studies that investigate the
predictive value for cardiovascular events are currently
ongoing and will provide more information on this topic in
the near future (Table 1)[ 23].
A recent study that showed a strong relation between
MRI vessel wall thickness and HDL-C was a study in
carriers of LCAT mutations [24￿]. In this study, 40 carriers
were compared to 40 age-matched controls. Carriers had
38% decreased HDL-C levels, which was accompanied
with a marked increase in vessel wall thickness when
compared to unaffected controls, indicating that decreased
HDL-C due to LCAT dysfunction leads to accelerated
atherogenesis.
Concerning the relation between HDL-C and plaque size
and composition assessed by MRI, no clear relationship
was found in epidemiologic studies. In the ARIC study,
carotid MRI was performed in 1769 subjects at baseline
and after 18 years of follow-up. There was neither a relation
between plaque size and HDL-C, nor was there a relation
between presence of a lipid-rich necrotic core and HDL-C
[25]. Similarly, no relation between lipid-rich necrotic core
presence and HDL-C was found in 214 patients selected
from the Multi-Ethnic Study of Atherosclerosis [26].
Interestingly, there was also a lack of relationship between
lipid-rich necrotic core presence and other traditional risk
factors. Reasons for this lack of relation with risk factors
remain to be elucidated. Potentially technical limitations for
identifying lipid-rich necrotic core may have played a role.
Another issue might be the fact that patient selection was
based on presence of advanced atherosclerosis in both
studies. Selecting such a population might restrict the range
of values and possible association with risk factors.
M R Io fv e s s e lw a l lt h i c k n e s sh a sa l s ob e e nu s e dt o
investigate the efficacy of HDL-C–raising compounds
(Table 1). Lee et al. [27] performed a double-blind,
randomized placebo-controlled MRI study to assess if
niacin on top of conventional statin therapy could reduce
carotid atherosclerosis progression. MRI scans were
performed at baseline and 1 year follow-up in 71 patients
with low HDL-C (<40 mg/dL) and either type 2 diabetes
with coronary heart disease (CHD) or carotid/peripheral
atherosclerosis and showed that niacin significantly
reduced progression of carotid wall thickness. Further-
more, an ongoing MRI trial, the dal-PLAQUE imaging
study (ClinicalTrials.gov Identifier: NCT00655473), is
currently investigating the efficacy of the cholesteryl ester
transferase inhibitor dalcetrapib. This multi-center, ran-
domized placebo-controlled trial is investigating the effect
of dalcetrapib therapy on plaque progression in 130
patients with CHD or CHD-risk equivalent. MRI scans
will be performed at baseline and after 6, 12, and
24 months of dalcetrapib therapy. Results are expected to
be published in 2011.
The Carotid Plaque Composition Study is a currently
ongoing study in 123 CAD patients that is investigating the
efficacy of niacin in combination with atorvastatin and
colesevelam on plaque size and composition [28].
Brachial Artery Endothelial Function Assessment
Endothelial cells form the inner lining of the vasculature and
are a key regulator in preserving vascular heath. B-mode
ultrasoundflow-mediatedvasodilatation(FMD)ofthebrachial
artery is a technique that can be utilized to assess beneficial
effects of HDL-C–raising drugs on endothelial function [29].
The measurement is done by assessing end-diastolic brachial
artery diameters continually before and after 5 min of forearm
280 Curr Atheroscler Rep (2011) 13:277–284ischemia (Fig. 1). The superimposed blood flow and
increased shear stress after ischemia stimulates local nitric
oxide (NO) release from the endothelium, resulting in
vasodilation.
Under standardized environmental conditions, with
adequate imaging equipment, protocols, analysis software,
and experienced sonographers, FMD has shown to be a
reproducible measurement (Table 1)[ 29]. A major advan-
tage of FMD is that effects of drugs can be observed after
short-term treatment, and due to the non-invasive nature of
this modality, measurements can be repeatedly performed in
a short period of time.
To assess the capability of FMD to predict future
cardiovascular events, the Cardiovascular Health Study was
conducted [30]. Baseline FMD measurements were per-
formed in 2792 adults aged 72 to 98 years and all
participants were followed for 5 years. This study showed
that FMD greater than the sex-specific median was a
significant predictor of future cardiovascular events, with a
hazard ratio of 0.91 (95% CI, 0.83–0.99; P=0.02 per unit SD
of FMD). Similar results were found in 3026 subjects of the
Multi-Ethnic Study of Atherosclerosis, in which FMD was
significantly associated with incident cardiovascular events,
with a hazard ratio of 0.84 (95% CI, 0.71–0.99; P=0.04 per
unit SD of FMD) (Table 1)[ 31￿￿].
Physiologic mechanisms linking HDL to endothelial
function and NO bioavailability have been established in
several experimentalstudies.Yuhannaetal. showedthatHDL
stimulates endothelial nitric oxide synthase (eNOS) via the
scavenger receptor B type I (SR-BI) receptor through a
process that requires ApoA-I binding. HDL-associated lyso-
phospholipids were shown to be responsible for the vaso-
dilatory effect of HDL via a lysophospholipid receptor
(sphingosine-1-phosphate receptor), causing Akt-mediated
activation of eNOS.
Yeboah et al. [32] showed in 2792 subjects in the
Cardiovascular Health Study that HDL-C was highly corre-
lated with FMD. Moreover, in 3026 subjects of the Multi-
Ethnic Study of Atherosclerosis, decreased HDL-C levels
were associated with decreased FMD, with a hazard ratio of
0.78 (95%CI, 0.64–0.96; P=0.020 per unit SD of FMD) [32].
Other clinical evidence of the relation between HDL-C and
endothelial function comes from studies in carriers of ApoA-I
gene defects. Heterozygote carriers of such mutations have a
50% decrease in ApoA-I and 63% decrease in serum HDL-C
l e v e l sa n dw e r ea l s oo b s e r v e dt oh a v em a r k e dr e d u c t i o ni n
FMD when compared to controls [7].
Regarding HDL-C–raising drugs, a few small FMD
studies investigating the effect of niacin have been
performed with mixed results (Table 1). Benj et al. [33]
observed that niacin improved FMD when compared to
placebo in 22 subjects. Warnholtz et al. [34] performed a
randomized, double-blind, placebo-controlled trial in 106
CAD patients investigating the efficacy of 12 weeks of
niacin therapy and found no effect on FMD, although some
benefit on FMD was observed in the lowest HDL-C tertile.
Infusion of reconstituted HDL (rHDL) was investigated in
studies by Spieker et al. [35] and Nieuwdorp et al. [36].
Endothelial function was measured by FMD as well as
venous occlusion plethysmography, and both studies showed
that rHDL infusion rapidly normalizes endothelium-
dependent vasodilation by increasing NO bioavailability.
Currently, a randomized, placebo-controlled trial (dal-
VESSEL) is being conducted to investigate the efficacy of
the CETP protein inhibitor dalcetrapib onFMD in 476 patients
with CAD or CAD-risk equivalents and HDL-C <50 mg/dL
(ClinicalTrials.gov identifier: NCT00655538) [37￿￿].
FDG-PET Imaging of Vessel Wall Inflammation
The inflammatory response to the accumulation of oxidized
lipids in the artery wall plays a pivotal role in the
atherosclerotic disease process, and plaque inflammation
is associated with plaque rupture and atherothrombotic
events. 18F-fluordeoxyglucose positron emission tomogra-
phy (FDG-PET) is a highly sensitive modality that can be
utilized as a surrogate imaging marker for vessel wall
inflammation (Fig. 1)[ 38]. The effect of HDL-C–raising
drugs on FDG uptake in the vessel wall can provide insight
in the anti-inflammatory property of HDL in the athero-
sclerotic disease process.
To obtain FDG-PET images, positron-emitting radio-
nuclides incorporated into a glucose analogue (FDG) are
injected into the circulation of a patient prior to imaging.
Subsequently, the circulating FDG will be actively taken up
by cells via glucose transporters. Inside the cells, FDG is
phosphorylated into FDG-6 phosphate by hexokinase and
not further metabolized. This leads to a relatively increased
uptake and retention of FDG in cells that are metabolically
active [38]. The positrons that are emitted by FDG travel a
short distance in the body (<1 mm) until they interact with
an electron, producing two gamma photons that travel out
of the body, in (almost) opposite directions, where they are
detected by the scintillators of the PET scanner.
Inflammatory cells, especially when they are activated,
have high metabolic activity, and therefore high FDG
uptake [38]. Studies in experimental atherosclerotic rabbit
models showed that FDG accumulates in atherosclerotic
lesions and correlates with the number of macrophages in
the plaque [39]. Also, in human endarterectomy studies,
FDG accumulation in plaque was shown to be correlated
with plaque macrophage content [40].
Rominger et al. [41￿] performed an FDG-PET imaging
study in 334 otherwise asymptomatic cancer patients with a
follow-up of 29 months and showed that target-to-
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with occurrence of future vascular events. Paulmier et al.
[42] performed FDG-PET in a cohort of 1140 patients
suffering from cancer, of which 45 were identified with high
FDG uptake in the large arteries, who were then matched for
age, gender, type of cancer, and conventional CVD risk
factors with 56 patients with low FDG uptake in the large
arteries. They showed that enhanced FDG uptake was
predictive for a history of CVD and the occurrence of
CVD in the 6 months after PET imaging [42]. Rudd et al.
[43] performed a carotid FDG-PET scan shortly after
symptom onset in eight patients suffering from TIA and
showed that symptomatic carotid artery plaques had higher
F D Gu p t a k et h a na s y m p t o m a t i cp l a q u e s .
The High Risk Plaque Initiative is a large, ongoing
epidemiologic study that includes FDG-PET imaging and
will provide more information on the predictive value of
FDG-PET in the near future [23].
The relation between FDG-PET and HDL-C levels and
other risk factors has also been investigated. Tahara et al. [44]
performed FDG-PET imaging in 261 patients recruited for
cancer screening and found an independent relation between
FDG uptake and HDL-C, waist circumference, hypertension,
insulin resistance, C-reactive protein levels, and ultrasound
CIMT. Rudd et al. [45] performed FDG-PET in 41 patients
with cardiovascular disease or at least three cardiovascular
risk factors and showed marked increased vessel wall
inflammation in patients with a history of CAD versus no
cardiovascular disease and also in men compared to women.
FDG uptake also correlated with serum levels of the
inflammatory biomarkers matrix metalloproteinase and neg-
atively correlated with adiponectin [45]. The relation with
HDL-C was not investigated in this study.
The fact that FDG-PET is a non-invasive measure of
vessel wall inflammation with excellent reproducibility [46]
has made this an attractive modality to assess efficacy of
cardiovascular drugs with anti-inflammatory properties
(Table 1).
Tahara et al. [47] imaged 43 patients suffering from
cancer disease with FDG-PET before and after 3 months of
medication with a low-dose statin (simvastatin, 20 mg
daily). They found a significant reduction in carotid artery
FDG uptake as compared to a placebo group [47].
Lee et al. [48] showed a 65% reduction in the number of
vascular regions that accumulated FDG in a group of 60
asymptomatic subjects after 17 months of lifestyle and
dietary modifications. Interestingly, both the studies by
Tahara et al. [47] and Lee et al. [48] found that the
magnitude of the FDG-PET signal reduction was closely
related with the rise in HDL-C.
Recently,astudyin99CADpatientsinvestigatedtheeffect
of a p38 mitogen-activated protein kinase (p38MAPK)
inhibitor on plaque inflammation as assessed by FDG-PET
and observed a marked decrease in FDG uptake in the carotid
arteries [49￿￿]. Another recent study compared the effect of
pioglitazone versus glimepiride therapy in 49 patients with
impaired glucose tolerance and observed a marked reduction
in FDG uptake in the pioglitazone group [50￿].
Concerning HDL-C–raising therapies, the ongoing multi-
center, randomized, placebo-controlled dal-PLAQUE imaging
study (ClinicalTrials.gov identifier: NCT00655473) is using
FDG-PET to investigate the efficacy of the cholesteryl ester
transferase inhibitor dalcetrapib. FDG-PET imaging of the
carotid and aortic arteries will be performed in 130 patients
with CHD or CHD-risk equivalent, at baseline and after 3 and
6 months of dalcetrapib therapy.
Conclusions
Imaging ofatherosclerosis can be utilized toassess efficacy as
well as provide pathophysiologic information on the mecha-
nism of action of novel of HDL-C–raising drugs. Much effort
has been made over the past decades to develop ultrasound,
MRI, and most recently FDG-PET to provide efficacy
measures that can be used to assist in decision making and
whetherornottoproceedwithnovelanti-atherogenicdrugsin
costlyandtime-consumingmortalityandmorbiditytrials.The
current armamentarium of imaging modalities is capable of
providing insight in drug effects on atherosclerosis progres-
sion, endothelial function, and vessel wall inflammation and
willplayacrucialroleinevaluatingemergingHDL-C–raising
compounds.
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